Forman S J, Blume K G
Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, California.
Hematol Oncol Clin North Am. 1990 Jun;4(3):517-33.
Allogeneic marrow transplantation has emerged as a curative therapy for many patients with acute leukemia. The ability to cure patients of their disease is dependent on the remission status of the patient. For patients with acute myelogenous leukemia, up to 60% of patients can become long-term, disease-free survivors, whereas a similar number of patients with high-risk acute lymphoblastic leukemia can also achieve cure of their disease. The improved results with marrow transplantation have allowed the application of this therapy for patients up to the age of 50 years. Even patients with therapy-related leukemias can benefit from this approach. Although relapse is still a problem in all remission stages, current studies suggest that improved preparatory regimens, in combination with better treatment of graft-versus-host disease and prevention of cytomegalovirus pneumonia, will continue to improve the overall results of this therapy for patients with acute leukemia.
异基因骨髓移植已成为许多急性白血病患者的一种治愈性疗法。治愈患者疾病的能力取决于患者的缓解状态。对于急性髓性白血病患者，高达60%的患者可成为长期无病生存者，而同样数量的高危急性淋巴细胞白血病患者也能治愈其疾病。骨髓移植取得的更好疗效使得该疗法可应用于年龄达50岁的患者。甚至与治疗相关的白血病患者也能从这种方法中获益。尽管复发在所有缓解阶段仍然是个问题，但目前的研究表明，改进的预处理方案，结合对移植物抗宿主病的更好治疗以及预防巨细胞病毒肺炎，将继续改善这种疗法对急性白血病患者的总体疗效。
